FDA Accepts Incyte's Ruxolitinib Cream US Application For Chronic Skin Disease

Under Priority Review status, the FDA has accepted Incyte Corporation's (NASDAQ: INCY) marketing application for review seeking approval for ruxolitinib cream.
Ruxolitinib is a selective JAK1/JAK2 inhibitor as a treatment for atopic dermatitis, a type of eczema characterized by inflammation and intense itch.
The company has submitted a Priority Review Voucher (PRV) along with the application for ruxolitinib cream. The use of the PRV shortens the review period by four months. The agency's action date is June 21.
Price Action: INCY increased 0.55% at $82 on last check Friday.